Abstract:The HIV-1 transactivator protein Tat interacts with the transactivation response element (TAR) at the three-nucleotide UCU bulge to facilitate the recruitment of transcription elongation factor-b (P-TEFb) and induce the transcription of the integrated proviral genome. Therefore, the Tat–TAR interaction, unique to the virus, is a promising target for developing antiviral therapeutics. Currently, there are no FDA-approved drugs against HIV-1 transcription, suggesting the need to develop novel inhibitors that specifically target HIV-1 transcription. We have identified potential candidates that effectively inhibit viral transcription in myeloid and T cells without apparent toxicity. Among these candidates, two molecules showed inhibition of viral protein expression. A molecular docking and simulation approach was used to determine the binding dynamics of these small molecules on TAR RNA in the presence of the P-TEFb complex, which was further validated by a biotinylated RNA pulldown assay. Furthermore, we examined the effect of these molecules on transcription factors, including the SWI/SNF complex (BAF or PBAF), which plays an important role in chromatin remodeling near the transcription start site and hence regulates virus transcription. The top candidates showed significant viral transcription inhibition in primary cells infected with HIV-1 (98.6). Collectively, our study identified potential transcription inhibitors that can potentially complement existing cART drugs to address the current therapeutic gap in current regimens. Additionally, shifting of the TAR RNA loop towards Cyclin T1 upon molecule binding during molecular simulation studies suggested that targeting the TAR loop and Tat-binding UCU bulge together should be an essential feature of TAR-binding molecules/inhibitors to achieve complete viral transcription inhibition.

Role of TAR RNA Binding Protein in HIV-1 Infection

RbAp48, a Novel Inhibitory Factor That Regulates the Transcription of Human Immunodeficiency Virus Type 1.

New insights into the function and therapeutic potential of RNA-binding protein TRBP in viral infection, chronic metabolic diseases, brain disorders and cancer

Opposite actions of two dsRNA-binding proteins PACT and TRBP on RIG-I mediated signaling

TDP-43 Controls HIV-1 Viral Production and Virus Infectiveness

The TAR Binding Dynamics and Its Implication in Tat Degradation Mechanism

Cellular Protein TTRAP Interacts with HIV-1 Integrase to Facilitate Viral Integration.

RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation

Retinoblastoma Binding Protein 4 Represses HIV-1 Long Terminal Repeat-Mediated Transcription by Recruiting NR2F1 and Histone Deacetylase.

HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules.

A Cofactor, TIP30, Specifically Enhances HIV-1 Tat-activated Transcription.

Interaction of Virion Protein Vpr of Human Immunodeficiency Virus Type 1 with Cellular Transcription Factor Sp1 and trans-Activation of Viral Long Terminal Repeat

Diverse roles of host RNA binding proteins in RNA virus replication.

AID Recruits the RNA Exosome to Degrade HIV ‐1 Nascent Transcripts Through Interaction with the Tat‐P‐ TEF B‐ TAR RNP Complex

Caspase-mediated processing of TRBP regulates apoptosis during viral infection

Enhanced NF-κB activation via HIV-1 Tat-TRAF6 cross-talk

Tumor Necrosis Factor--Induced Protein 8-Like 2 Negatively Regulates Innate Immunity Against RNA Virus by Targeting RIG-I in Macrophages

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages

TAR RNA selective targeting ruthenium(II) complexes as HIV-1 reverse transcriptase inhibitors: On exploring structure-activity relationships of multiple positions

Role of Retinoblastoma Protein-Associated Protein 48 (RBBP4) in HIV-1 Latency